ALEXA SCANLAN: Open Payments
NPI 1447973300 · MAYER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$349 in 19 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $407 · 2025 $349
Food & beverage: $349
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $67 |
| Novo Nordisk Inc | 2 | $56 |
| AstraZeneca Pharmaceuticals LP | 3 | $49 |
| GlaxoSmithKline, LLC. | 3 | $48 |
| Xeris Pharmaceuticals, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $20 |
| Amgen Inc. | 1 | $18 |
| Exact Sciences Corporation | 1 | $17 |
| PFIZER INC. | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
Products named: Ozempic, AIRSUPRA, TRELEGY ELLIPTA, MOUNJARO, RECORLEV, Veozah, ZEPBOUND, OTEZLA.
Industry payments across AZ — which companies pay providers there.
